Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.
Jasper Therapeutics, a US-based blood transplant conditioning agent spinout of Stanford University and drug producer Amgen, on Thursday increased its series A round past $50m with a $14.1m tranche led by drug firm Roche’s Venture Fund.
The extension involved unnamed additional investors and came after the initial $35m close last month co-led by venture capital firm Qiming Venture Partners and bioscience-focused investment firm Abingworth.
Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust…
